Non-Hodgkin Lymphoma – Pipeline Review
H2 2012

Non-Hodgkin Lymphoma – Pipeline Review H2 2012

Non-Hodgkin Lymphoma - Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H2 2012', provides an overview of the Non-Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Non-Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma. 'Non-Hodgkin Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Non-Hodgkin Lymphoma.
• A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Non-Hodgkin Lymphoma therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

• Introduction
• Global Markets Direct Report Coverage
• Non-Hodgkin Lymphoma Overview
• Therapeutics Development
• An Overview of Pipeline Products for Non-Hodgkin Lymphoma
• Non-Hodgkin Lymphoma Therapeutics under Development by Companies
• Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes
• Late Stage Products
• Comparative Analysis
• Mid Clinical Stage Products
• Comparative Analysis
• Early Clinical Stage Products
• Comparative Analysis
• Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Non-Hodgkin Lymphoma Therapeutics - Products under Development by Companies
• Non-Hodgkin Lymphoma Therapeutics - Products under Investigation by Universities/Institutes
• Companies Involved in Non-Hodgkin Lymphoma Therapeutics Development
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd.
• Kyowa Hakko Kirin Co., Ltd.
• Abbott Laboratories
• Amgen Inc.
• Sanofi-Aventis
• Eli Lilly and Company
• Seattle Genetics, Inc.
• Genentech, Inc.
• Antigenics, Inc.
• Biotec Pharmacon ASA
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Emergent BioSolutions Inc.
• Gamida Cell Ltd.
• Celltrion, Inc.
• ZIOPHARM Oncology, Inc.
• Millennium Pharmaceuticals, Inc.
• Novartis AG
• Astellas Pharma Inc.
• Cephalon, Inc.
• Eisai Co., Ltd.
• Gedeon Richter Plc.
• Human Genome Sciences, Inc.
• ImmunoGen, Inc.
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sigma-Tau S.p.A.
• SuperGen, Inc.
• Cell Therapeutics, Inc.
• Alfacell Corporation
• Celgene Corporation
• Incyte Corporation
• Hana Biosciences, Inc.
• IMMUNOMEDICS, INC
• Idera Pharmaceuticals, Inc.
• MethylGene Inc
• NexMed, Inc.
• Northwest Biotherapeutics, Inc.
• Accentia Biopharmaceuticals, Inc.
• Allos Therapeutics, Inc
• Cytokinetics, Inc
• TopoTarget A/S
• Mundipharma International Limited
• Pharmacyclics, Inc.
• MorphoSys AG
• Takara Bio Inc.
• Sareum Holdings plc
• Innate Pharma SA
• Transgene Biotek Ltd
• Spectrum Pharmaceuticals, Inc.
• Affimed Therapeutics AG
• Chipscreen Biosciences Ltd
• Memgen, LLC.
• Abiogen Pharma S.p.A.
• Ascenta Therapeutics, Inc.
• Semafore Pharmaceuticals, Inc.
• ProNAi Therapeutics, Inc.
• Yaupon Therapeutics, Inc.
• Fate Therapeutics, Inc.
• Xencor, Inc.
• PharmaMar, S.A.
• VentiRx Pharmaceuticals, Inc.
• Biokine Therapeutics Ltd.
• SymbioTec GmbH
• TaiGen Biotechnology Co., Ltd.
• Astellas Pharma GmbH
• EpiZyme, Inc.
• Non-Hodgkin Lymphoma - Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Drug Profiles
• StemEx - Drug Profile
• MAbThera - Drug Profile
• MAbThera - Drug Profile
• MLN8237 - Drug Profile
• Adcetris - Drug Profile
• Adcetris - Drug Profile
• PCI-32765 - Drug Profile
• BiovaxID - Drug Profile
• Chidamide - Drug Profile
• Marqibo - Drug Profile
• Forodesine - Drug Profile
• Mechlorethamine Gel - Drug Profile
• Folotyn - Drug Profile
• CHOP-14 + Alemtuzumab - Drug Profile
• Bendamustine + Rituximab - Drug Profile
• Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile
• Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile
• CMC-544 - Drug Profile
• Inotuzumab Ozogamicin + Rituxan - Drug Profile
• Revlimid - Drug Profile
• RG7159 + Bendamustine - Drug Profile
• Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile
• CHOP14 + G-CSF + MabCampath + Autologous Stem Cell Transplantation - Drug Profile
• Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile
• CHEOP + Radiation Therapy - Drug Profile
• Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Autologus Stem Cell Transplantation - Drug Profile
• Fludarabine + Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
• Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
• Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
• Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone + G-CSF + Alemtuzumab - Drug Profile
• Lenalidomide - Drug Profile
• BBR 2778 - Drug Profile
• Umbilical Cord Blood Transplantation - Drug Profile
• CHOP Regimen + Filgrastim + Cytarabine + Etoposide + Leucovorin Calcium + Melphalan + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Hydrocortisone + Autologous Stem Cell Transplantation + Radiation Therapy - Drug Profile
• Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile
• Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile
• Ifosfamide + Amsacrine + Etoposide - Drug Profile
• Rituxan + CHOP Chemotherapy - Drug Profile
• Cisplatin + Dexamethasone + Cytarabine + Rituximab + Autologus Stem Cell Transplantation - Drug Profile
• Mega-CHOEP + Rituximab + Autologous Stem Cell Transplantation - Drug Profile
• Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Therapeutic Hydrocortisone + Vinblastine - Drug Profile
• Chlorambucil + Dexamethasone + Interferon Alfa - Drug Profile
• R-CHOP14 + Darbepoetin Alfa - Drug Profile
• Rituximab-HDS - Drug Profile
• Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile
• Mitoxantrone + Cyclophosphamide + Vincristine + Prednisolone - Drug Profile
• Rituximab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile
• Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile
• Ibritumomab Tiuxetan - Drug Profile
• Interferon Alfa-2b - Drug Profile
• Rituximab - Drug Profile
• Zolinza + Velcade - Drug Profile
• Non-Hodgkin Lymphoma Therapeutics - Drug Profile Updates
• Non-Hodgkin Lymphoma Therapeutics - Discontinued Products
• Non-Hodgkin Lymphoma Therapeutics - Dormant Products
• Non-Hodgkin Lymphoma - Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer
• List of Tables
  • Number of Products Under Development for Non-Hodgkin Lymphoma, H2 2012
  • Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2012
  • Number of Products under Development by Companies, H2 2012
  • Number of Products under Development by Companies, H2 2012 (Contd..1)
  • Number of Products under Development by Companies, H2 2012 (Contd..2)
  • Number of Products under Development by Companies, H2 2012 (Contd..3)
  • Number of Products under Development by Companies, H2 2012 (Contd..4)
  • Number of Products under Development by Companies, H2 2012 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2012
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8)
  • Comparative Analysis by Late Stage Development, H2 2012
  • Comparative Analysis by Mid Clinical Stage Development, H2 2012
  • Comparative Analysis by Early Clinical Stage Development, H2 2012
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
  • Products under Development by Companies, H2 2012
  • Products under Development by Companies, H2 2012 (Contd..1)
  • Products under Development by Companies, H2 2012 (Contd..2)
  • Products under Development by Companies, H2 2012 (Contd..3)
  • Products under Development by Companies, H2 2012 (Contd..4)
  • Products under Development by Companies, H2 2012 (Contd..5)
  • Products under Development by Companies, H2 2012 (Contd..6)
  • Products under Development by Companies, H2 2012 (Contd..7)
  • Products under Development by Companies, H2 2012 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2012
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..11)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..13)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..14)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..15)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..16)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..17)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..18)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..19)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..20)
  • Products under Investigation by Universities/Institutes, H2 2012 (Contd..21)
  • Bristol-Myers Squibb Company, H2 2012
  • Johnson & Johnson, H2 2012
  • Boehringer Ingelheim GmbH, H2 2012
  • F. Hoffmann-La Roche Ltd., H2 2012
  • Kyowa Hakko Kirin Co., Ltd., H2 2012
  • Abbott Laboratories, H2 2012
  • Amgen Inc., H2 2012
  • Sanofi-Aventis, H2 2012
  • Eli Lilly and Company, H2 2012
  • Seattle Genetics, Inc., H2 2012
  • Genentech, Inc., H2 2012
  • Antigenics, Inc., H2 2012
  • Biotec Pharmacon ASA, H2 2012
  • Gilead Sciences, Inc., H2 2012
  • Merck & Co., Inc., H2 2012
  • Emergent BioSolutions Inc., H2 2012
  • Gamida Cell Ltd., H2 2012
  • Celltrion, Inc., H2 2012
  • ZIOPHARM Oncology, Inc., H2 2012
  • Millennium Pharmaceuticals, Inc., H2 2012
  • Novartis AG, H2 2012
  • Astellas Pharma Inc., H2 2012
  • Cephalon, Inc., H2 2012
  • Eisai Co., Ltd., H2 2012
  • Gedeon Richter Plc., H2 2012
  • Human Genome Sciences, Inc., H2 2012
  • ImmunoGen, Inc., H2 2012
  • Ono Pharmaceutical Co., Ltd., H2 2012
  • Pfizer Inc., H2 2012
  • Sigma-Tau S.p.A., H2 2012
  • SuperGen, Inc., H2 2012
  • Cell Therapeutics, Inc., H2 2012
  • Alfacell Corporation, H2 2012
  • Celgene Corporation, H2 2012
  • Incyte Corporation, H2 2012
  • Hana Biosciences, Inc., H2 2012
  • IMMUNOMEDICS, INC, H2 2012
  • Idera Pharmaceuticals, Inc., H2 2012
  • MethylGene Inc, H2 2012
  • NexMed, Inc., H2 2012
  • Northwest Biotherapeutics, Inc., H2 2012
  • Accentia Biopharmaceuticals, Inc., H2 2012
  • Allos Therapeutics, Inc, H2 2012
  • Cytokinetics, Inc, H2 2012
  • TopoTarget A/S, H2 2012
  • Mundipharma International Limited, H2 2012
  • Pharmacyclics, Inc., H2 2012
  • MorphoSys AG, H2 2012
  • Takara Bio Inc., H2 2012
  • Sareum Holdings plc, H2 2012
  • Innate Pharma SA, H2 2012
  • Transgene Biotek Ltd, H2 2012
  • Spectrum Pharmaceuticals, Inc., H2 2012
  • Affimed Therapeutics AG, H2 2012
  • Chipscreen Biosciences Ltd, H2 2012
  • Memgen, LLC., H2 2012
  • Abiogen Pharma S.p.A., H2 2012
  • Ascenta Therapeutics, Inc., H2 2012
  • Semafore Pharmaceuticals, Inc., H2 2012
  • ProNAi Therapeutics, Inc., H2 2012
  • Yaupon Therapeutics, Inc., H2 2012
  • Fate Therapeutics, Inc., H2 2012
  • Xencor, Inc., H2 2012
  • PharmaMar, S.A., H2 2012
  • VentiRx Pharmaceuticals, Inc., H2 2012
  • Biokine Therapeutics Ltd., H2 2012
  • SymbioTec GmbH, H2 2012
  • TaiGen Biotechnology Co., Ltd., H2 2012
  • Astellas Pharma GmbH, H2 2012
  • EpiZyme, Inc., H2 2012
  • Assessment by Monotherapy Products, H2 2012
  • Assessment by Combination Products, H2 2012
  • Assessment by Stage and Route of Administration, H2 2012
  • Assessment by Stage and Molecule Type, H2 2012
  • Non-Hodgkin Lymphoma Therapeutics - Drug Profile Updates
  • Non-Hodgkin Lymphoma Therapeutics - Discontinued Products
  • Non-Hodgkin Lymphoma Therapeutics - Discontinued Products (Contd..1)
  • Non-Hodgkin Lymphoma Therapeutics - Discontinued Products (Contd..2)
  • Non-Hodgkin Lymphoma Therapeutics - Discontinued Products (Contd..3)
  • Non-Hodgkin Lymphoma Therapeutics - Discontinued Products (Contd..4)
  • Non-Hodgkin Lymphoma Therapeutics - Discontinued Products (Contd..5)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..1)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..2)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..3)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..4)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..5)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..6)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..7)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..8)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..9)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..10)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..11)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..12)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..13)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..14)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..15)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..16)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..17)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..18)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..19)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..20)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..21)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..22)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..23)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..24)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..25)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..26)
  • Non-Hodgkin Lymphoma Therapeutics - Dormant Products (Contd..27)
• List of Figures
  • Number of Products under Development for Non-Hodgkin Lymphoma, H2 2012
  • Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2012
  • Products under Development by Companies, H2 2012
  • Products under Investigation by Universities/Institutes, H2 2012
  • Late Stage Products, H2 2012
  • Mid Clinical Stage Products, H2 2012
  • Early Clinical Stage Products, H2 2012
  • Discovery and Pre-Clinical Stage Products, H2 2012
  • Assessment by Monotherapy Products, H2 2012
  • Assessment by Combination Products, H2 2012
  • Assessment by Route of Administration, H2 2012
  • Assessment by Stage and Route of Administration, H2 2012
  • Assessment by Molecule Type, H2 2012
  • Assessment by Stage and Molecule Type, H2 2012